Ameriprise
XERS icon

Ameriprise’s Xeris Biopharma Holdings XERS Stock Holding History

Ameriprise’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
143,285
+1,137
+0.8% +$7.26K ﹤0.01% 3348
2026
Q1 		$824K Sell
142,148
-1,315
-0.9% -$8.72K ﹤0.01% 3389
2025
Q4 		$1.13M Sell
143,463
-10,705
-7% -$84.3K ﹤0.01% 3280
2025
Q3 		$1.25M Buy
154,168
+5,140
+3% +$34.1K ﹤0.01% 3243
2025
Q2 		$696K Sell
149,028
-19,074
-11% -$87.4K ﹤0.01% 3408
2025
Q1 		$923K Sell
168,102
-41,821
-20% -$169K ﹤0.01% 3242
2024
Q4 		$712K Sell
209,923
-7,166
-3% -$23.1K ﹤0.01% 3395
2024
Q3 		$619K Sell
217,089
-2,817
-1% -$7.24K ﹤0.01% 3413
2024
Q2 		$495K Sell
219,906
-733,330
-77% -$1.48M ﹤0.01% 3413
2024
Q1 		$2.11M Buy
953,236
+433,115
+83% +$1.12M ﹤0.01% 2844
2023
Q4 		$1.22M Sell
520,121
-67,817
-12% -$125K ﹤0.01% 3110
2023
Q3 		$1.09M Sell
587,938
-4,570
-0.8% -$10.5K ﹤0.01% 3099
2023
Q2 		$1.55M Buy
592,508
+23,261
+4% +$59.2K ﹤0.01% 2992
2023
Q1 		$928K Sell
569,247
-820
-0.1% -$1.03K ﹤0.01% 3187
2022
Q4 		$758K Hold
570,067
– – ﹤0.01% 3253
2022
Q3 		$890K Buy
570,067
+156,573
+38% +$259K ﹤0.01% 3170
2022
Q2 		$638K Sell
413,494
-4,270
-1% -$9.01K ﹤0.01% 3310
2022
Q1 		$1.07M Buy
417,764
+367,163
+726% +$897K ﹤0.01% 3188
2021
Q4 		$168K Buy
50,601
+2,401
+5% +$5.19K ﹤0.01% 3811
2021
Q3 		$118K Sell
48,200
-400
-0.8% -$1.16K ﹤0.01% 3768
2021
Q2 		$198K Buy
48,600
+4,905
+11% +$18.7K ﹤0.01% 3757
2021
Q1 		$197K Buy
43,695
+33,680
+336% +$182K ﹤0.01% 3709
2020
Q4 		$49K Sell
10,015
-7,095
-41% -$35.5K ﹤0.01% 3725
2020
Q3 		$101K Buy
+17,110
New +$68.4K ﹤0.01% 3639

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Ameriprise's XERS Position: Q2 2026 in Review

Ameriprise increased its Xeris Biopharma Holdings (XERS) stake by 0.8% in Q2 2026, buying an estimated $7.26K and bringing the position to 143,285 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3348.

Ameriprise first reported a position in XERS in Q3 2020 and has held it in 24 quarters since. The position peaked at $2.11M in Q1 2024. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Ameriprise held 143,285 shares of Xeris Biopharma Holdings worth $1.13M as of Q2 2026.
  • Ameriprise bought 1,137 Xeris Biopharma Holdings shares in Q2 2026, an estimated $7.26K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3348 holding.
  • Ameriprise first reported a position in Xeris Biopharma Holdings in Q3 2020 and has held it in 24 quarters since.
  • Ameriprise's Xeris Biopharma Holdings position peaked at $2.11M in Q1 2024.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.